Proteome Sciences PLC - London-based drug development services provider - Says it has repaid in full its outstanding loan and associated interest, totalling GBP824,424, to Vulpes Investment Management Private Ltd, as originally announced in July 2018 and amended in March last year.
In mid-May, Proteome Sciences said revenue for 2022 increased by 52% to GBP7.8 million, from GBP5.1 million in 2021. Biomarker services grew by 45% to GBP2.8 million and TMT revenue increased by 56% to GBP5.0 million. It said it was confident that progress over the recent years has created an "excellent" platform for further development of the group.
Current stock price: 4.86 pence, up 2.5%
12-month change: up 26%
By Greg Rosenvinge, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
Proteome (PRM)